Tomosynthesis

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Retrieved on: 
Tuesday, November 28, 2023
GE HealthCare, RSNA, ICAD, Breast cancer, Radiology, Workflow, Research, Inc., Breast, Health, Cancer, AI, Artificial intelligence, Diagnosis, Calcification, DBT, Tomosynthesis, Medical imaging

As breast cancer becomes the most commonly diagnosed cancer worldwide, iCAD’s AI solutions are integral to addressing critical issues in breast imaging - such as access, burnout, variability, equity, and cost.

Key Points: 
  • As breast cancer becomes the most commonly diagnosed cancer worldwide, iCAD’s AI solutions are integral to addressing critical issues in breast imaging - such as access, burnout, variability, equity, and cost.
  • GE HealthCare’s MyBreastAI Suite, with iCAD's three key AI-enabled solutions from iCAD, aims to streamline workflow and help clinicians in accelerating breast cancer detection and delivering more personalized and effective breast care.
  • Providing Lesion Scores and Case Scores, ProFound Detection aids in clinical decision-making, workload prioritization, and could help reduce burnout.
  • "Key AI-powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be integrated with GE HealthCare’s MyBreastAI Suite which is an exciting way to advance our ongoing collaboration to continue deliver breast cancer detection and diagnostic innovation," continued Brown.

TGH Imaging has Expanded Its Hologic Genius™ 3D Mammography™ Services Across 18 Centers in 4 Counties

Retrieved on: 
Monday, May 15, 2023
The Lancet, Conant, E pluribus unum, Enterprise, Hologic, 3D, Gates Rubber Company v. Bando Chemical Industries, Ltd., et al, Breast cancer, Breast, Radiology, Cancer, CAD, Woman, Tomosynthesis, Macdonald, Synthesis, 2D, Mammography, SM, Patient, Tampa General Hospital, JAMA Oncology, Digital, FDA, SVP, Computer-aided, JAMA, Medical imaging

TAMPA, Fla., May 15, 2023 /PRNewswire/ -- As the need for more advanced technology continues to grow, TGH Imaging is increasing patient access across four counties for breast cancer screening by adding Genius™ 3D Mammography™ exams made by Hologic to 18 locations in Hillsborough, Pasco, Pinellas and Palm Beach counties. Also called tomosynthesis, 3D mammography is a form of mammography that creates a 3D image of the breast that can better detect breast cancer.

Key Points: 
  • Also called tomosynthesis, 3D mammography is a form of mammography that creates a 3D image of the breast that can better detect breast cancer.
  • "3D mammography has become the superior choice in breast imaging," said Dr. JoAnn Gierbolini, a Women's subspecialized radiologist at TGH Imaging and collaborative assistant professor at the USF Morsani College of Medicine.
  • A 3D mammogram can be done in conjunction with a synthesized 2D mammogram and does not require additional exam time or compression.
  • "3D Mammography is the standard of care in breast imaging, and we're thrilled to expand this service further throughout TGH Imaging," says Sherri Lewman, SVP of Enterprise Imaging at Tampa General Hospital.

iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference

Retrieved on: 
Wednesday, May 3, 2023
Risk, Cleveland Clinic, Society, ICAD, Medicine, Journal of Medical Screening, Social impact of profound hearing loss, Breast, Woman, Intelligence, DBT, Tomosynthesis, Siemens, Radiology, Incidence, Journal, Patient, Inc., Interval, Reading, Cancer, Science Translational Medicine, Health professional, AI, FDA, SBI, Mammography, III, Breast cancer, National Harbor, Maryland, Medical imaging, MD

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National Harbor, MD.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National Harbor, MD.
  • Attendees are invited to visit the iCAD booth #507 to see the Company’s Breast AI Suite in action and learn how leading clinicians worldwide are overcoming imaging challenges, including decreasing the incidence of interval cancers.
  • “While mammography screening has improved in recent decades and the introduction of digital breast tomosynthesis (DBT) offers many clinical advantages, it also creates enormous amounts of data.
  • iCAD’s Breast AI Suite also includes PowerLook Density Assessment, which automates the process of breast density reporting and empowers clinicians to further personalize breast cancer screening recommendations for patients.

New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection without Increasing the Rate of Recalls and Reveals Critical Clues to Inform Clinical Decisions

Retrieved on: 
Thursday, April 20, 2023
Real-World Evidence, American Roentgen Ray Society, Malignancy, ICAD, University, FP, Biopsy, Profound Mysteries, HI, D.O, Abnormality, Cancer, FN, Woman, ARRS, University of Pennsylvania, Research, Tomosynthesis, DBT, Assistant, Radiology, Medical director, Patient, Inc., Risk, Knowledge, FDA, Health, Breast cancer, Medical imaging, Medical device

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies.
  • One study demonstrated that ProFound AI improved radiologists' performance in detecting breast cancer and providing better accuracy, without increasing abnormal interpretation rates or the rate of recalls.
  • iCAD’s ProFound AI increased cancer detection rates and positive predictive value for cancer among abnormal interpretations (PPV1), without increasing abnormal interpretation rates across the radiologists studied.
  • Researchers concluded ProFound AI resulted in clinically relevant increases in cancer detection, without increasing the rate of recalls.

RSNA: Huge Study Finds Tomosynthesis Better at Breast Cancer Detection

Retrieved on: 
Tuesday, March 14, 2023
Linda, Publishing, Breast cancer, Division, Radiological Society of North America, Ageing, Patient, University, RSNA, Society, Radiation, Breast, Hospital, Cancer, American Cancer Society, Health, Mortality, Woman, Education, DBT, Research, Tomosynthesis, 2D, Medical imaging, Radiology, New York University

OAK BROOK, Ill., March 14, 2023 /PRNewswire-PRWeb/ -- In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results of the study were published today, March 14, in Radiology, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone.
  • OAK BROOK, Ill., March 14, 2023 /PRNewswire-PRWeb/ -- In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone.
  • Breast cancer is the most common cancer among women in the United States.
  • While breast cancer mortality has been on the decline since the late 1980s due to improvements in early detection and treatment, it still remains the leading cause of cancer death among women.

Carestream Collaborates with Robarts Research Institute To Advance Translational Cardiothoracic and Pulmonary Disease Research

Retrieved on: 
Tuesday, February 7, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Radiology, Health Technology, Medical Devices, Research, Hospitals, Science, Associate professor, Robarts, Physician, Medical imaging, Anatomy, Robarts Research Institute, CT, Acquisition, DT, Patient, Lung, DE, Software, Doctor of Philosophy, Intelligence, Partnership, Innovation, Radiography, Multimedia, Intelligence Advanced Research Projects Activity, Tomosynthesis, Schulich School of Medicine & Dentistry, Western University, Medical physics, Medicine, Nursing, Pharmaceutical industry, Carestream Health

Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the clinical value of digital X-ray, digital tomosynthesis and dual energy technologies to help improve the outcomes of patients with cardiothoracic and pulmonary diseases.

Key Points: 
  • Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the clinical value of digital X-ray, digital tomosynthesis and dual energy technologies to help improve the outcomes of patients with cardiothoracic and pulmonary diseases.
  • Carestream is providing a state-of-the-art imaging system and software to Robarts, the research institute of Schulich School of Medicine & Dentistry at Western University in Canada, to advance its multidisciplinary translational research.
  • View the full release here: https://www.businesswire.com/news/home/20230207005386/en/
    Carestream Health is partnering with Robarts Research to demonstrate the clinical value of digital tomosynthesis and dual energy technologies to help improve patient outcomes.
  • (Graphic: Business Wire)
    The equipment installed at Robarts mirrors what is found in the region’s clinical settings and will support collaborative, multidisciplinary research that bridges bench to bedside.

Fujifilm to Unveil New Medical Imaging Advances at the RSNA 2022 Conference

Retrieved on: 
Monday, November 21, 2022
Heart, Architecture, McCormick Place, Diagnosis, Tomosynthesis, Health, Laboratory, Gastroenterology, Anatomy, Mammography, AI, Digital radiography, Hospital, RSNA, Knowledge, Acquisition, Algorithm, Spine, Radiological Society of North America, ISS, Electricity, X-ray, MRI, Artificial intelligence, CEDM, Sale, OEM, Scoliosis, Google Images, CT scan, Radiology, DBT, FDR, Lithium, CT, Nursing, FDA, Enterprise imaging, Medical imaging, Renewable energy, Innovation, Fujifilm

When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.

Key Points: 
  • When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.
  • To learn more about Fujifilms presence at RSNA 2022 and to schedule an on-site meeting, please click here.
  • Fujifilms innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery.
  • The award-winning Synapse Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record.

Global Mammography Market Report 2022: A $4.67 Billion Market by 2030 - Size, Share & Trends Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Health, General Health, FDA, National Breast Cancer Foundation, Ageing, Canadian National Breast Screening Study, Non-governmental organization, Siemens Healthineers, ICAD, Software, ICAD Inc., Digital, Y-ME National Breast Cancer Organization, Mammography, CDC, U.S. FDA, USD, USFDA, Woman, National Breast Cancer Foundation (United States), DBT, Artificial intelligence, Film screening, Profound Pharma, Growth, CAD, Organization, Tomosynthesis, Diagnosis, Medical imaging, Medical device, Hospital

The "Mammography Market Size, Share & Trends Analysis Report by Product (Film Screen, Digital), by Technology (Breast Tomosynthesis, CAD, Digital), by End-use (Specialty Clinics, Hospitals), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mammography Market Size, Share & Trends Analysis Report by Product (Film Screen, Digital), by Technology (Breast Tomosynthesis, CAD, Digital), by End-use (Specialty Clinics, Hospitals), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • For instance, the National Breast Cancer Screening Programme in the Netherlands, for example, was created for women aged 50 to 75.
  • According to the program, women in this age bracket were invited for a mammogram every two years.
  • Furthermore, the use of Artificial Intelligence (AI) in 3D mammography has reduced exam time while maintaining image quality.

Ferrum Health to Offer iCAD's Breast AI Technologies within its Women's Health AI Hub

Retrieved on: 
Thursday, November 24, 2022
Radiology, ICAD, Algorithm, DBT, ICAD Inc., Entrepreneurship, Breast cancer, Mammography, Breast, Woman, Tomosynthesis, 3D, Social impact of profound hearing loss, Health, Calcification, AI, Ferrum, Cancer, Neurology, Medical imaging, Medical device

SUNNYVALE, Calif., Nov. 23, 2022 /PRNewswire/ -- Ferrum Health, a leader in healthcare enterprise AI solutions, announces an agreement with iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, to offer iCAD's breast AI solutions on Ferrum Health's platform. The onboarding of iCAD's Profound AI® for Digital Breast Tomosynthesis (DBT) and PowerLook® Density Assessment tools expands Ferrum's suite of AI algorithms within its Women's Health AI Hub.

Key Points: 
  • The onboarding of iCAD's Profound AI for Digital Breast Tomosynthesis (DBT) and PowerLook Density Assessment tools expands Ferrum's suite of AI algorithms within its Women's Health AI Hub.
  • "iCAD's breast AI solutions are playing a significant role in the rapid evolution of breast cancer screening," stated Pelu Tran , CEO and Co-Founder of Ferrum Health.
  • Ferrum Health simplifies the selection, validation, and deployment of healthcare AI with a secure and scalable enterprise AI platform.
  • Ferrum Health developed an enterprise AI deployment platform to improve patient outcomes by democratizing health systems' access to the most innovative and impactful clinical AI technologies worldwide.

Professor László Tabár Joins DetectedX as the Medical Director of Breast Cancer Imaging

Retrieved on: 
Monday, November 21, 2022
Online, Nobel Prize, Classification, Breast, Woman, Radiology, University, Breast cancer, Medical director, Education, Bolster, RSNA, Multimedia, Educational technology, Lung cancer, Book, COVID-19, Artificial intelligence, Radiological Society of North America, 2D, Medical imaging, Neoplasm, Diagnosis, Tomosynthesis, Mammography, North Hall

SYDNEY, Nov. 21, 2022 /PRNewswire/ -- DetectedX, leaders in intelligent interactive educational technology, announced today that Professor László Tabár, a Nobel Prize Nominee and visionary physician, academic and educator, has joined the company as Medical Director of Breast Cancer Imaging.

Key Points: 
  • "Professor Tabr has worked relentlessly to enhance the early detection of breast cancer for more than 40 years.
  • We are proud to have Professor Tabr bring his incredible experience and expertise to the DetectedX team to expand and enhance our breast imaging educational content and help us improve radiology education around the world," said Professor Patrick Brennan, CEO DetectedX and Chair, Diagnostic Imaging, the University of Sydney.
  • DetectedX will showcase the new breast imaging educational content from Professor Tabr at the upcoming Radiological Society of North America (RSNA) meeting, November 27-December 1, 2022 ( North Hall #7951 ).
  • DetectedX was founded to help doctors and radiologists worldwide to diagnose cases of breast cancer, lung cancer, and COVID-19 faster and more accurately.